检索结果-南通市图书馆

2019第一届全国口腔颌面-头颈肿瘤学术大会——聚合引领、协同发展

作者：苏文杨宏宇北京大学深圳医院

Purpose/Background: Oral squamous cell carcinoma（OSCC） is an oral and maxillofacial malignancy with a high incidence worldwide. Accumulating evidence indicates that circular RNAs（circRNAs） play a vital role in modulating tumor development. However, the mechanism of circRNA action in human OSCC remains largely *** and Methods:By using high-throughput transcriptome sequencing technology, we conducted a comprehensive study of circRNAs in human OSCC. The effect of circRNA hsairc005379 on OSCC tissues and cell lines was monitored by qRT-PCR, Transwell assay, flow cytometry, and western blot analysis. Xenograft mouse models were used to assess tumor growth and animal survival.

关键词： Oral squamous cell carcinoma Circular RNAs egfr pathway Cetuximab Epithelial-mesenchymal transition

来源： cnki会议评论

在线全文

cnki会议

学校读者我要写书评

暂无评论

ZiyuglycosideⅡinhibits the growth of digestive system cancer cells through multiple mechanisms

引用

Chinese Journal of Natural Medicines 2021年第5期19卷 351-363页

作者： ZHONG Ying LI Xiao-Yu ZHOU Fei CAI Ya-Jie SUN Rong LIU Run-Ping The Second Hospital Cheeloo College of MedicineShandong UniversityJinan 250033China School of Chinese Materia Medica Beijing University of Chinese MedicineBeijing 100029China

Digestive system cancers,including liver,gastric,colon,esophageal and pancreatic cancers,are the leading cause of cancers with high morbidity and mortality,and the question of their clinical treatment is still *** studies have indicated that ZiyuglycosideⅡ(ZYGⅡ),the major bioactive ingredient extract from Sanguisorba officinalis L.,significantly inhibits the growth of various cancer ***,the selective anti-tumor effects of ZYGⅡagainst digestive system cancers are not systemically *** this study,we reported the anti-cancer effect of ZYGⅡon esophageal cancer cells(OE21),cholangiocarcinoma cells(Hu CCT1),gastric cancer cells(BGC-823),liver cancer cells(Hep G2),human colonic cancer cells(HCT116),and pancreatic cancer cells(PANC-1).We also found that ZYGⅡinduced cell cycle arrest,oxidative stress and mitochondrial *** pharmacology analysis suggested that UBC,egfr and IKBKG are predicted targets of ZYGⅡ.egfr signaling was suggested as the critical pathway underlying the anti-cancer effects of ZYGⅡand both docking simulation and western blot analysis demonstrated that ZYGⅡwas a potential egfr ***,our results showed synergistic inhibitory effects of ZYGⅡand chemotherapy 5-FU on the growth of cancer *** summary,ZYGⅡare effective anti-tumor agents against digestive *** systemic evaluation of the anti-cancer activities in vitro and in vivo and characterization of underlying mechanism will promote the development of novel supplementary therapeutic strategies based on ZYGⅡfor the treatment of digestive system cancers.

关键词： ZiyuglycosideⅡ Digestive system cancers Network pharmacology egfr pathway

来源：

维普期刊数据库

同方期刊数据库评论

在线全文

学校读者我要写书评

暂无评论

Research progress on KRAS mutations in colorectal cancer

引用

Journal of Cancer Metastasis and Treatment 2021年第1期7卷 364-380页

作者： Marco Cefalì Samantha Epistolio Maria Celeste Palmarocchi Milo Frattini Sara De Dosso Department of Medical Oncology Oncology Institute of Southern SwitzerlandBellinzona 6500Switzerland Institute of Pathology Laboratory of Molecular PathologyLocarno 6600Switzerland Universitàdella Svizzera Italiana Lugano 6900Switzerland

The RAS gene family,responsible for signal transduction within the mitogen activated protein kinase(MAPK)and phosphatidylinositol 3 kinase(PI3K)pathways,is frequently involved in carcinogenesis,and alterations in its member genes can be detected,with variable frequency,in a wide variety of solid and hematological *** alterations may behave as prognostic-predictive biomarkers and driver mutations,making them an interesting therapeutic *** their discovery,many strategies have been pursued to act on their signaling ***,in clinical practice,KRAS,the most prominent member of the RAS gene family,represents an especially elusive target in most malignancies;pathway inhibition is carried out upstream,on the egfr receptor,or downstream,most frequently on the BRAF/MEK/ERK ***,clinically relevant direct RAS inhibition has been successfully achieved with the development of potent and selective covalent inhibitors of KRAS c.34G>T(p.G12C).These latest-generation drugs represent both a new and interesting tool in the therapeutic armamentarium and a symbolic end to the myth of KRAS ***,their clinical relevance and appropriate place in treatment strategies remain to be determined.

关键词： KRAS targeted therapies egfr pathway MAPK colorectal cancer

来源：

维普期刊数据库评论

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

欢迎您,

建议与咨询留下您的常用邮箱和电话号码，以便我们向您反馈解决方案和替代方法

时间限定

文献类型

馆藏选择

核心期刊

语言

文献类型

帮助

文字说明：

检索规则说明：

检索范例：

分类表

所选分类

限定检索结果

文献类型

馆藏范围

日期分布

学科分类号

主题

机构

作者

语言

在线全文

在线全文

在线全文

请选择保存的检索档案：

请选择收藏分类：

通借通还

欢迎您,

建议与咨询 留下您的常用邮箱和电话号码，以便我们向您反馈解决方案和替代方法

时间限定

文献类型

馆藏选择

核心期刊

语言

文献类型

帮助

文字说明：

检索规则说明：

检索范例：

分类表

所选分类

限定检索结果

文献类型

馆藏范围

日期分布

学科分类号

主题

机构

作者

语言

在线全文

在线全文

在线全文

请选择保存的检索档案： 新增检索档案 确定 取消

请选择收藏分类： 新增自定义分类 确定 取消

通借通还

建议与咨询留下您的常用邮箱和电话号码，以便我们向您反馈解决方案和替代方法

请选择保存的检索档案：

请选择收藏分类：